Skip to main
ZYME
ZYME logo

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc has demonstrated promising clinical trial results, particularly with Ziihera in combination with chemotherapy, which revealed statistically significant improvements in progression-free survival and overall survival compared to the control arm, enhancing the drug's approval probability to 90%. In the third quarter of 2025, the company reported a narrower net loss of $0.26 per share, indicating better-than-expected financial performance compared to prior forecasts. Additionally, adjustments to the discounted cash flow (DCF) valuation method, including a lowered discount rate, suggest a more favorable financial outlook and an increase in projected stock valuation.

Bears say

Zymeworks Inc faces significant challenges that contribute to a negative financial outlook, including its inability to scale up manufacturing for biparatopic antibodies and secure timely European approval for zanidatamab. Additionally, the company is grappling with risks associated with partnerships, as well as poorer-than-expected commercial uptake of its products, which could exacerbate projected net losses, estimated at $1.75 per share for full-year 2025. There are also concerns regarding potential clinical trial failures due to safety and efficacy issues, alongside long-term dilution risks that may jeopardize shareholder value.

Zymeworks Inc (ZYME) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 7 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.